phosphorylcholine has been researched along with Kahler Disease in 29 studies
Phosphorylcholine: Calcium and magnesium salts used therapeutically in hepatobiliary dysfunction.
phosphocholine : The phosphate of choline; and the parent compound of the phosphocholine family.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The combination of lenalidomide-dexamethasone is active in multiple myeloma (MM)." | 9.16 | Perifosine plus lenalidomide and dexamethasone in relapsed and relapsed/refractory multiple myeloma: a Phase I Multiple Myeloma Research Consortium study. ( Alsina, M; Anderson, KC; Gardner, L; Giusti, K; Harvey, C; Hideshima, T; Jakubowiak, AJ; Kandarpa, M; Kaufman, JL; Kraftson, S; Poradosu, E; Richardson, PG; Ross, CW; Sportelli, P; Zimmerman, T, 2012) |
| "The successful clinical development of thalidomide, bortezomib, and lenalidomide not only transformed the therapeutic management of multiple myeloma (MM) but also catalyzed a renewed interest in the development of additional classes of novel agents for this disease." | 8.85 | Emerging treatments for multiple myeloma: beyond immunomodulatory drugs and bortezomib. ( Anderson, KC; Chauhan, D; Hideshima, T; Klippel, S; Laubach, JP; McMillin, DW; Mitsiades, CS; Munshi, NC; Richardson, PG, 2009) |
| " Perifosine is a novel alkyl-lysophospholipid that can induce apoptosis in multiple myeloma (MM) tumor cells, both in vitro and in vivo." | 7.74 | Alkyl phospholipid perifosine induces myeloid hyperplasia in a murine myeloma model. ( Anderson, KC; Bronson, R; Catley, L; Chauhan, D; Hideshima, T; Munshi, NC; Neri, P; Song, W; Tai, YT; Tassone, P, 2007) |
| "Perifosine is a synthetic novel alkylphospholipid, a new class of antitumor agents which targets cell membranes and inhibits Akt activation." | 5.33 | Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. ( Anderson, KC; Catley, L; Chauhan, D; Hideshima, T; Ishitsuka, K; Mitsiades, C; Munshi, NC; Podar, K; Raje, N; Richardson, PG; Yasui, H, 2006) |
| "The combination of lenalidomide-dexamethasone is active in multiple myeloma (MM)." | 5.16 | Perifosine plus lenalidomide and dexamethasone in relapsed and relapsed/refractory multiple myeloma: a Phase I Multiple Myeloma Research Consortium study. ( Alsina, M; Anderson, KC; Gardner, L; Giusti, K; Harvey, C; Hideshima, T; Jakubowiak, AJ; Kandarpa, M; Kaufman, JL; Kraftson, S; Poradosu, E; Richardson, PG; Ross, CW; Sportelli, P; Zimmerman, T, 2012) |
| "The treatment of multiple myeloma has evolved significantly over the past 2 decades due to the use of high-dose chemotherapy and autologous stem cell transplantation, and the subsequent introduction of the immunomodulatory agents (thalidomide and lenalidomide) and the proteasome inhibitor (bortezomib)." | 4.91 | Emerging therapies in multiple myeloma. ( El-Amm, J; Tabbara, IA, 2015) |
| "The successful clinical development of thalidomide, bortezomib, and lenalidomide not only transformed the therapeutic management of multiple myeloma (MM) but also catalyzed a renewed interest in the development of additional classes of novel agents for this disease." | 4.85 | Emerging treatments for multiple myeloma: beyond immunomodulatory drugs and bortezomib. ( Anderson, KC; Chauhan, D; Hideshima, T; Klippel, S; Laubach, JP; McMillin, DW; Mitsiades, CS; Munshi, NC; Richardson, PG, 2009) |
| "Perifosine is a novel targeted oral Akt inhibitor currently in Phase III clinical development for treatment of colorectal cancer (CRC, in combination with capecitabine) and multiple myeloma (MM, in combination with bortezomib and dexamethasone)." | 3.78 | Perifosine , an oral, anti-cancer agent and inhibitor of the Akt pathway: mechanistic actions, pharmacodynamics, pharmacokinetics, and clinical activity. ( Anderson, KC; Eng, C; Hideshima, T; Kolesar, J; Richardson, PG, 2012) |
| "We have found that resveratrol (trans-3,4',5-trihydroxystilbene) induced apoptosis in multiple myeloma (MM) and T-cell leukemia cells through coclustering of Fas/CD95 death receptor and lipid rafts, whereas normal lymphocytes were spared." | 3.75 | Involvement of mitochondria and recruitment of Fas/CD95 signaling in lipid rafts in resveratrol-mediated antimyeloma and antileukemia actions. ( Gajate, C; Mollinedo, F; Reis-Sobreiro, M, 2009) |
| " Perifosine is a novel alkyl-lysophospholipid that can induce apoptosis in multiple myeloma (MM) tumor cells, both in vitro and in vivo." | 3.74 | Alkyl phospholipid perifosine induces myeloid hyperplasia in a murine myeloma model. ( Anderson, KC; Bronson, R; Catley, L; Chauhan, D; Hideshima, T; Munshi, NC; Neri, P; Song, W; Tai, YT; Tassone, P, 2007) |
| "Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment." | 2.50 | New approaches to management of multiple myeloma. ( Cavallo, F; Genadieva-Stavric, S; Palumbo, A, 2014) |
| "Perifosine is a synthetic novel alkylphospholipid, a new class of antitumor agents which targets cell membranes and inhibits Akt activation." | 1.33 | Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. ( Anderson, KC; Catley, L; Chauhan, D; Hideshima, T; Ishitsuka, K; Mitsiades, C; Munshi, NC; Podar, K; Raje, N; Richardson, PG; Yasui, H, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (20.69) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 10 (34.48) | 29.6817 |
| 2010's | 10 (34.48) | 24.3611 |
| 2020's | 3 (10.34) | 2.80 |
| Authors | Studies |
|---|---|
| Gokhale, S | 1 |
| Lu, W | 1 |
| Zhu, S | 1 |
| Liu, Y | 1 |
| Hart, RP | 1 |
| Rabinowitz, JD | 1 |
| Xie, P | 1 |
| Yamazaki, H | 1 |
| Shirakawa, K | 1 |
| Matsumoto, T | 1 |
| Kazuma, Y | 1 |
| Matsui, H | 1 |
| Horisawa, Y | 1 |
| Stanford, E | 1 |
| Sarca, AD | 1 |
| Shirakawa, R | 1 |
| Shindo, K | 1 |
| Takaori-Kondo, A | 1 |
| Camilleri, M | 1 |
| Richards, H | 1 |
| Pomplun, S | 1 |
| Wilson, A | 1 |
| Checkley, A | 1 |
| Rabin, N | 1 |
| El-Amm, J | 1 |
| Tabbara, IA | 1 |
| Orlowski, RZ | 1 |
| Genadieva-Stavric, S | 1 |
| Cavallo, F | 1 |
| Palumbo, A | 1 |
| Iida, S | 1 |
| Ri, M | 1 |
| David, E | 1 |
| Sinha, R | 1 |
| Chen, J | 1 |
| Sun, SY | 1 |
| Kaufman, JL | 2 |
| Lonial, S | 2 |
| Mitsiades, CS | 1 |
| Hideshima, T | 10 |
| Chauhan, D | 5 |
| McMillin, DW | 1 |
| Klippel, S | 1 |
| Laubach, JP | 1 |
| Munshi, NC | 6 |
| Anderson, KC | 10 |
| Richardson, PG | 6 |
| Reis-Sobreiro, M | 1 |
| Gajate, C | 2 |
| Mollinedo, F | 2 |
| Cirstea, D | 1 |
| Rodig, S | 1 |
| Santo, L | 1 |
| Pozzi, S | 1 |
| Vallet, S | 3 |
| Ikeda, H | 2 |
| Perrone, G | 1 |
| Gorgun, G | 1 |
| Patel, K | 1 |
| Desai, N | 1 |
| Sportelli, P | 4 |
| Kapoor, S | 1 |
| Vali, S | 1 |
| Mukherjee, S | 1 |
| Raje, N | 4 |
| Schmidt-Hieber, M | 1 |
| Dabrowski, R | 1 |
| Weimann, A | 1 |
| Aicher, B | 1 |
| Lohneis, P | 1 |
| Busse, A | 1 |
| Thiel, E | 1 |
| Blau, IW | 1 |
| Wolf, J | 1 |
| Jakubowiak, A | 1 |
| Zonder, J | 1 |
| Irwin, D | 1 |
| Densmore, J | 1 |
| Krishnan, A | 1 |
| Bar, M | 1 |
| Martin, T | 1 |
| Schlossman, R | 1 |
| Ghobrial, IM | 3 |
| Munshi, N | 2 |
| Laubach, J | 1 |
| Allerton, J | 1 |
| Colson, K | 1 |
| Poradosu, E | 2 |
| Gardner, L | 2 |
| Yosifov, DY | 1 |
| Reufsteck, C | 1 |
| Konstantinov, SM | 1 |
| Berger, MR | 1 |
| Eng, C | 1 |
| Kolesar, J | 1 |
| Jakubowiak, AJ | 1 |
| Zimmerman, T | 1 |
| Alsina, M | 1 |
| Kandarpa, M | 1 |
| Kraftson, S | 1 |
| Ross, CW | 1 |
| Harvey, C | 1 |
| Giusti, K | 1 |
| Viseux, V | 1 |
| Schoenlaub, P | 1 |
| Danhier, S | 1 |
| Vilque, JP | 1 |
| Plantin, P | 1 |
| Catley, L | 3 |
| Yasui, H | 2 |
| Ishitsuka, K | 1 |
| Mitsiades, C | 2 |
| Podar, K | 3 |
| Tai, YT | 4 |
| Fulciniti, M | 1 |
| Song, W | 2 |
| Leiba, M | 1 |
| Li, XF | 1 |
| Rumizen, M | 1 |
| Burger, P | 1 |
| Morrison, A | 1 |
| Tassone, P | 2 |
| Richardson, P | 2 |
| Neri, P | 1 |
| Bronson, R | 1 |
| Kiziltepe, T | 1 |
| Ocio, E | 1 |
| Okawa, Y | 1 |
| Hideshima, H | 1 |
| Huston, A | 1 |
| Leleu, X | 1 |
| Jia, X | 1 |
| Moreau, AS | 1 |
| Ngo, HT | 1 |
| Runnels, J | 1 |
| Anderson, J | 1 |
| Alsayed, Y | 1 |
| Roccaro, A | 1 |
| Hatjiharissi, E | 1 |
| Roodman, DG | 1 |
| Benca, R | 1 |
| Quintáns, J | 1 |
| Kearney, JF | 1 |
| Flood, PM | 1 |
| Schreiber, H | 1 |
| Morrison, SL | 1 |
| Johnson, MJ | 1 |
| Herzenberg, LA | 1 |
| Oi, VT | 1 |
| Cook, WD | 1 |
| Rudikoff, S | 2 |
| Giusti, AM | 1 |
| Scharff, MD | 1 |
| Padlan, EA | 1 |
| Segal, DM | 1 |
| Cohen, GH | 1 |
| Davies, DR | 1 |
| Potter, M | 1 |
| Gutman, GA | 1 |
| Warner, NL | 1 |
| Harris, AW | 1 |
| Bowles, A | 1 |
| Baldo, BA | 1 |
| Fletcher, TC | 1 |
| Pepys, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| An Open-Label Phase I/II Study of the Safety and Efficacy of Perifosine and Bortezomib With or Without Dexamethasone for Patients With Relapsed or Refractory Multiple Myeloma Previously Treated With Bortezomib[NCT00401011] | Phase 1/Phase 2 | 84 participants (Actual) | Interventional | 2006-08-31 | Completed | ||
| An Open-Label Phase I Study of the Safety of Perifosine in Combination With Lenalidomide and Dexamethasone for Patients With Relapsed or Refractory Multiple Myeloma[NCT00415064] | Phase 1 | 32 participants (Actual) | Interventional | 2006-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 reviews available for phosphorylcholine and Kahler Disease
| Article | Year |
|---|---|
Emerging therapies in multiple myeloma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Histone Deacetylas | 2015 |
Novel agents for multiple myeloma to overcome resistance in phase III clinical trials.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Clinical Trials, Phase III as | 2013 |
New approaches to management of multiple myeloma.
Topics: Adult; Age Factors; Aged; Antibodies, Monoclonal; Antineoplastic Agents; Boron Compounds; Boronic Ac | 2014 |
[Determinants of sensitivity to proteasome inhibitors and strategies to overcome acquired resistance to bortezomib in multiple myeloma].
Topics: Activating Transcription Factor 3; Activating Transcription Factor 4; Antineoplastic Combined Chemot | 2014 |
Emerging treatments for multiple myeloma: beyond immunomodulatory drugs and bortezomib.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Screening Assays, Antitumor; Enzyme | 2009 |
3 trials available for phosphorylcholine and Kahler Disease
| Article | Year |
|---|---|
Perifosine plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma previously treated with bortezomib: results of a multicenter phase I/II trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Borte | 2011 |
Perifosine plus lenalidomide and dexamethasone in relapsed and relapsed/refractory multiple myeloma: a Phase I Multiple Myeloma Research Consortium study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Dose-Response Relationsh | 2012 |
Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Bone Marrow Cells; Boronic | 2007 |
21 other studies available for phosphorylcholine and Kahler Disease
| Article | Year |
|---|---|
Elevated Choline Kinase α-Mediated Choline Metabolism Supports the Prolonged Survival of TRAF3-Deficient B Lymphocytes.
Topics: Animals; B-Lymphocytes; Cell Line; Cell Survival; Choline; Choline Kinase; Gene Expression Regulatio | 2020 |
APOBEC3B reporter myeloma cell lines identify DNA damage response pathways leading to APOBEC3B expression.
Topics: Antibodies, Monoclonal, Humanized; Bortezomib; Cell Line, Tumor; Cell Nucleus; CRISPR-Cas Systems; C | 2020 |
Leishmaniasis as an unusual cause of pancytopenia in a patient receiving immunomodulatory therapy for myeloma.
Topics: Aged; Antiprotozoal Agents; Combined Modality Therapy; Drug Substitution; Endemic Diseases; Humans; | 2020 |
Perifosine synergistically enhances TRAIL-induced myeloma cell apoptosis via up-regulation of death receptors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; CASP8 and FADD-Like Ap | 2008 |
Involvement of mitochondria and recruitment of Fas/CD95 signaling in lipid rafts in resveratrol-mediated antimyeloma and antileukemia actions.
Topics: Antineoplastic Agents; Apoptosis; bcl-X Protein; BH3 Interacting Domain Death Agonist Protein; Boron | 2009 |
Dual inhibition of akt/mammalian target of rapamycin pathway by nanoparticle albumin-bound-rapamycin and perifosine induces antitumor activity in multiple myeloma.
Topics: Albumins; Animals; Apoptosis; Autophagy; Bone Marrow Cells; Caspases; Cell Line, Tumor; Cell Prolife | 2010 |
In vitro cytotoxicity of the novel antimyeloma agents perifosine, bortezomib and lenalidomide against different cell lines.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bor | 2012 |
Interleukin-6, osteopontin and Raf/MEK/ERK signaling modulate the sensitivity of human myeloma cells to alkylphosphocholines.
Topics: Antineoplastic Agents; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm | 2012 |
Perifosine , an oral, anti-cancer agent and inhibitor of the Akt pathway: mechanistic actions, pharmacodynamics, pharmacokinetics, and clinical activity.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Ca | 2012 |
[Multiple cutaneous plasmocytoma treated with topical applications of miltefosine].
Topics: Administration, Topical; Aged; Antineoplastic Agents; Female; Humans; Multiple Myeloma; Phosphorylch | 2004 |
Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells.
Topics: Cell Division; Cell Line, Tumor; Flow Cytometry; Growth Substances; Humans; Multiple Myeloma; Oncoge | 2006 |
Edelfosine and perifosine induce selective apoptosis in multiple myeloma by recruitment of death receptors and downstream signaling molecules into lipid rafts.
Topics: Apoptosis; Caspase 8; Cell Line, Tumor; Cell Proliferation; fas Receptor; Fas-Associated Death Domai | 2007 |
Alkyl phospholipid perifosine induces myeloid hyperplasia in a murine myeloma model.
Topics: Animals; Apoptosis; Cell Line; Female; Hematopoiesis; Humans; Hyperplasia; Leukocytosis; Mice; Multi | 2007 |
Inhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cells.
Topics: Animals; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Down-Regulation | 2007 |
Targeting Akt and heat shock protein 90 produces synergistic multiple myeloma cell cytotoxicity in the bone marrow microenvironment.
Topics: Benzoquinones; Bone Marrow; Cell Cycle; Cell Division; Cell Line, Tumor; Cell Survival; DNA Replicat | 2008 |
Studies on phosphorylcholine-specific T cell idiotypes and idiotype-specific immunity.
Topics: Animals; Antibody Formation; Cell Division; Choline; DNA, Neoplasm; Epitopes; Female; Immunoglobulin | 1980 |
Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains.
Topics: Animals; Antibodies; Antigens; Binding Sites, Antibody; Chimera; DNA, Recombinant; Humans; Immunoglo | 1984 |
Somatic mutation in a cultured mouse myeloma cell affects antigen binding.
Topics: Amino Acid Sequence; Animals; Antigen-Antibody Reactions; Binding Sites, Antibody; Cell Line; Hapten | 1982 |
Structure of a phosphorycholine-binding mouse myeloma Fab.
Topics: Binding Sites, Antibody; Choline; Crystallography; Epitopes; Haptens; Immunochemistry; Immunoglobuli | 1975 |
Use of [75Se]selenomethionine in immunoglobulin biosynthetic studies.
Topics: Animals; Culture Media; Electrophoresis, Polyacrylamide Gel; Immunoglobulins; Immunosorbents; Mice; | 1978 |
Isolation of a peptido-polysaccharide from the dermatophyte Epidermophyton floccosum and a study of its reaction with human C-reactive protein and a mouse anti-phosphorylcholine myeloma serum.
Topics: Animals; Antigen-Antibody Reactions; C-Reactive Protein; Epidermophyton; Humans; Immunoelectrophores | 1977 |